Related Experiment Video
Updated: Jul 20, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Current and future therapy for chronic hepatitis C virus liver disease
1Department of Medicine 111E, Building 200, Room A1-1, Veterans Administration Medical Center, 79, Middleville Road, Northport, NY 11768, USA. Info@findadoc.com
Current Drug Targets. Infectious Disorders
|October 8, 2003
Summary
Pegylated interferons combined with ribavirin offer the highest sustained virological response rates for chronic hepatitis C virus (HCV) infection. Novel HCV therapies are under development but not expected for several years.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C virus (HCV) infection treatment relies on interferon therapy.
- Pegylated interferons offer improved outcomes over non-pegylated forms.
- Ribavirin and amantadine show synergistic effects with interferon.
Purpose of the Study:
- To review current antiviral therapies for chronic HCV.
- To explore the role of viral dynamics in understanding drug mechanisms.
- To discuss emerging therapeutic agents for HCV.
Main Methods:
- Review of current literature on HCV antiviral treatments.
- Analysis of viral dynamic studies in humans to understand interferon mechanisms.
- Discussion of novel therapeutic agents in development.
Main Results:
- Pegylated interferons combined with ribavirin yield the highest sustained virological response (SVR) rates.
- Viral dynamic studies in humans aid in understanding interferon's mechanism of action.
- New HCV therapeutics are in development, but clinical availability is 3-5 years away.
Conclusions:
- Current standard of care involves pegylated interferons and ribavirin for optimal SVR.
- Understanding HCV replication dynamics is crucial for developing new treatments.
- Future HCV therapies are anticipated but require further validation.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...